Enhancing NRF2 signaling via tert-butylhydroquinone (tBHQ) treatment or adenoviral Nrf2 gene transfer also protects AD model mice from Aβ toxicity by upregulating NRF2 target genes and reducing the phosphorylation of p66Shc, a marker of oxidative stress susceptibility [87]. The gene discussed is NFE2L2; the disease is Alzheimer disease.